“Conclusions:
• Even in late-stage disease, an ultra-sensitive ctDNA platform is critically important for accurately tracking and predicting response to therapy.
• ctDNA profiling is complementary to imaging, allowing for more granular assessment of patient response to therapy.
• Ultra-sensitive ctDNA profiling correlates with the patients’ best response and tumor size dynamics.
• Tumor molecule PPM dynamics are prognostic of patient response to immunotherapy.”
